Compare MVIS & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MVIS | DCTH |
|---|---|---|
| Founded | 1993 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 271.6M | 311.7M |
| IPO Year | 2010 | 2015 |
| Metric | MVIS | DCTH |
|---|---|---|
| Price | $0.65 | $9.54 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $2.25 | ★ $22.00 |
| AVG Volume (30 Days) | ★ 7.4M | 335.0K |
| Earning Date | 03-04-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 23.91 | ★ 107.53 |
| EPS | N/A | ★ 0.07 |
| Revenue | ★ $664,000.00 | N/A |
| Revenue This Year | $529.06 | $24.54 |
| Revenue Next Year | $168.46 | $33.15 |
| P/E Ratio | ★ N/A | $132.57 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.51 | $8.12 |
| 52 Week High | $1.73 | $18.23 |
| Indicator | MVIS | DCTH |
|---|---|---|
| Relative Strength Index (RSI) | 47.49 | 53.64 |
| Support Level | $0.51 | $8.90 |
| Resistance Level | $0.73 | $10.17 |
| Average True Range (ATR) | 0.06 | 0.32 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 58.06 | 61.67 |
Microvision Inc is engaged in developing a lidar sensor to be used in automotive safety and autonomous driving applications. Its lidar sensor uses laser beam scanning (LBS) technology, which is based on systems that include micro-electrical mechanical systems (MEMS), laser diodes, opto-mechanics, electronics, algorithms, and software. The company has also developed solutions for Augmented Reality, Interactive Displays, and Consumer Lidars.
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.